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Abstract
Overgrowth disorders are a heterogeneous group of conditions characterised by increased growth
parameters and variable other clinical features, such as intellectual disability and facial
dysmorphism1. To identify novel causes of human overgrowth we performed exome sequencing in
10 proband-parent trios and detected two de novo DNMT3A mutations. We identified 11
additional de novo mutations through DNMT3A sequencing of a further 142 individuals with
overgrowth. The mutations were all located in functional DNMT3A domains and protein
modelling suggests they interfere with domain-domain interactions and histone binding. No
similar mutations were present in 1000 UK population controls (13/152 vs 0/1000; P<0.0001).
Mutation carriers had a distinctive facial appearance, intellectual disability and increased height.
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DNMT3A encodes a key methyltransferase essential for establishing the methylation imprint in
embryogenesis and is commonly somatically mutated in acute myeloid leukaemia2-4. Thus
DNMT3A joins an emerging group of epigenetic DNA and histone modifying genes associated
with both developmental growth disorders and haematological malignancies5.
The control of human growth is highly complex and influenced by common and rare genetic
variation6. The study of human overgrowth syndromes, which are characterised by increased
prenatal and postnatal growth relative to age-related peers, has led to significant insights into
fundamental biological processes involved in growth control1. As many growth disorders
present as non-familial cases with a distinctive phenotype we hypothesised that de novo
gene mutations may underlie some cases. To investigate this we are conducting trio-based
exome sequencing in individuals with overgrowth and their parents using the Illumina
TruSeq exome enrichment array. We are performing sequencing with an Illumina HiSeq
2000, aligning the data with Stampy, performing variant calling with Platypus, variant
annotation with SAVANT and identifying potential de novo variants using a custom R
script.
Review of the first 10 trios revealed two with apparent de novo mutations in DNMT3A
(DNA cytosine 5 methyltransferase 3A), which was of immediate interest because of the
functional relationship of this gene with EZH2, a known overgrowth predisposition gene we
previously identified as the cause of Weaver syndrome7,8. By Sanger sequencing we
confirmed the mutations, an inframe deletion p.Trp297del in COG0274 and a
nonsynonymous mutation, p.Leu648Pro in COG0553, were present in the proband but not in
the parents (Table 1, Supplementary Figure 1).
To further evaluate the role of DNMT3A, we sequenced the full coding sequence and intron-
exon boundaries of the gene by Sanger sequencing in a further 142 individuals with
overgrowth in whom mutations in NSD1, EZH2 and PTEN and dysregulation of the 11p15
growth regulatory region had been excluded, and for whom parental DNA was also
available (Supplementary Table 1). We identified an additional 11 de novo DNMT3A
mutations. Thus in total, we found 13 different de novo DNMT3A mutations in 152
individuals with overgrowth phenotypes: 10 nonsynonymous mutations, two small
frameshifting insertions and one inframe deletion (Figure 1, Table 1, Supplementary Figure
1). These data establish DNMT3A mutations as a cause of a novel human disorder, which we
have termed ‘DNMT3A overgrowth syndrome’.
A consistent phenotype, characterised by a distinctive facial appearance, tall stature and
intellectual disability, was evident amongst the thirteen individuals with de novo DNMT3A
mutations (Figure 2, Table 1). The facial gestalt was characterised by a round face, heavy,
horizontal eyebrows and narrow palpebral fissures (Figure 2). Height was increased in all
individuals ranging from 1.8 to 4.2 (mean 3.0) standard deviations above the mean. Head
circumference was also increased ranging from 1.2 to 5.1 (mean 2.5) standard deviations
above the mean. Intellectual disability, which was described as moderate in 11 individuals
and mild in the remaining two, is also a key feature of the condition. Other, less frequent
clinical features were variably present (Table 1). More detailed phenotyping in larger series
are required to evaluate if these are real associations of DNMT3A mutations and to better
define the clinical spectrum of this new overgrowth syndrome.
In eukaryotic DNA, methylation preferentially occurs at cytosine bases which are converted
to 5-methylcytosine by four DNA methyltransferase enzymes: DNMT3A, DNMT3B,
DNMT1 and DNMT3L2. DNMT3A and DNMT3B are essential for the establishment of
new methylation marks following erasure of parental methylation patterns during early
embryonic development and for the establishment of sex-dependent methylation marks of
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imprinted genes during gametogenesis9-11. By contrast, DNMT1 is essential for the
maintenance and conservation of DNA methylation marks after DNA replication10.
DNMT3L does not possess inherent enzymatic activity but appears to physically interact
with DNMT3A and stimulate its enzymatic activity12-14.
DNMT3A contains three functional domains: a proline-tryptophan-tryptophan-proline
(PWWP) domain; an ATRX-DNMT3A-DNMT3L-type zinc finger (ADD) domain and a C
terminal DNA methyltransferase domain (Figure 1). It is noteworthy that all the mutations
we identified were located in these domains. None were present in 1000 exomes from a UK
population control series that were sequenced and analysed in a similar fashion. Moreover,
no other frameshifting or nonsynonymous mutations in domains were present in the control
exomes; four nonsynonymous variants were detected, but all were outside the functional
domains (Figure 1). These data provide further evidence that the DNMT3A mutations in
cases are pathogenic (13/152 vs 0/1000, P<0.0001).
DNMT3A is one of the most frequently mutated genes in acute myeloid leukemia
(AML)3,4,15. Somatic DNMT3A mutations are detected in approximately one third of
cytogenetically normal AML and have also been reported in other haematological
neoplasms, such as myelodysplasia (MDS)16,17. Over half the somatic DNMT3A mutations
target a single residue, Arg882, with the remainder being nonsynonymous and truncating
mutations scattered through the gene 3,15. The somatic mutational spectra thus differs from
the de novo mutations we identified in overgrowth cases; we did not detect any Arg882
mutations and only two of the mutations we report, Arg749Cys and Pro904Leu, are also in
the 167 confirmed somatic DNMT3A mutations in haematological malignancies in the
COSMIC database (Supplementary Table 2).
Protein structure modelling suggests the Arg882 somatic mutations affect DNA binding and
functional analyses demonstrate mutations at this residue result in reduced methyltransferase
activity, possibly through a dominant-negative mechanism4,15,18. To explore the potential
impact of the DNMT3A overgrowth mutations we undertook protein structure modelling
which revealed the residues targeted by nonsynonymous mutations in the MTase domain
appear to be located at the interaction interface with the ADD domain, whereas those in the
ADD domain are close to the histone H3 binding region (Figure 3). The Arg767 residue in
the MTase domain that is mutated by a frameshifting insertion is situated at the interface
between DNMT3A and DNMT3L. Thus, whilst none of the overgrowth mutations appear
likely to affect DNA binding, their position and the role of the ADD domain in the
recognition of unmethylated lysine 4 of histone H3 suggest they may interfere with domain-
domain interactions and histone binding, thereby disrupting de novo methylation19.
Taken together these data are intriguing as they show both clear differences and some
overlap between the DNMT3A mutational spectra in malignancies and overgrowth. The
mechanism of pathogenesis in DNMT3A overgrowth syndrome is currently unclear though
a simple haploinsufficiency model appears unlikely given the small proportion of truncating
mutations. Of note, parents of Dnmt3a knockout mice are grossly phenotypically normal,
though it is unclear whether this is because loss of function of one Dnmt3a copy is not
associated with overgrowth, or because the overgrowth phenotype is too subtle to detect in
mice9. Further functional and mutational analyses will be of interest, to extend and
illuminate these observations. Long-term follow-up of individuals with DNMT3A
overgrowth syndrome, with particular focus on cancer incidence, will also be of interest. To
date, none of the probands have developed malignancies, though the oldest is only 29 years
of age. Haematological malignancies with somatic DNMT3A mutations typically occur in
middle-aged individuals3,4, and it is thus possible that an increased cancer risk only
manifests at older ages.
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DNMT3A joins an emerging family of genes with dual roles in the pathogenesis of
syndromic overgrowth and myeloid neoplasms. Other similar genes include EZH2 and
NSD15. The overgrowth phenotypes associated with EZH2 and NSD1 constitutional
mutations, which are called Weaver and Sotos syndrome respectively, are similar to each
other and to DNMT3A overgrowth syndrome5,8,20. Somatic EZH2 mutations, both
activating and inactivating, occur in AML and poor prognosis myeloproliferative neoplasms
and myelodysplastic syndromes15,21. Somatic NSD1 point mutations are rare4 but the
NUP90-NSD1 fusion protein, generated through the recurrent translocation, t(5;11)
(q35.3;p15.5) is present in approximately 5% of childhood acute myeloid leukaemia22. Both
EZH2 and NSD1 are histone methyltransferases that play key roles in regulation of
transcription through histone modification and chromatin modelling. EZH2 catalyses the
trimethylation of lysine residue 27 in histone H3 (H3K27me3) and is associated with
transcriptional repression, whereas NSD1 preferentially catalyses methylation of lysine
residue 36 of histone H3 (H3K36) and is primarily associated with transcriptional
activation23,24. Of note, another gene involved in chromatin modification that is often
mutated in AML and MDS, ASXL1, is also associated with a growth disorder15,25.
Constitutional de novo truncating ASXL1 mutations cause Bohring-Opitz syndrome, a rare
disorder characterised by severe undergrowth, severe intellectual disability, a characteristic
facial appearance and flexion deformities25. This suggests other epigenetic regulatory genes
somatically mutated in haematological malignancies, such as TET2, IDH1 and IDH2 would
be worth evaluating in developmental growth disorders15.
METHODS
Patient samples
Individuals with overgrowth were recruited through the Childhood Overgrowth Study. The
research has approval from the London Multicentre Ethics Committee (Reference: MREC/
01/2/44) and informed consent was obtained from all participants and/or families. DNA was
extracted from peripheral blood and was available from all probands and their parents.
Detailed phenotypic information, through a standardised questionnaire and photographs was
also obtained. Specific consent to publish facial photographs was obtained. A full list of
collaborators is given in the Supplementary Note.
Control samples
We used lymphocyte DNA from 1000 population-based controls obtained from the 1958
Birth Cohort Collection, a continuing follow-up of persons born in the United Kingdom in
one week in 1958. Biomedical assessment was undertaken during 2002-2004 at which blood
samples and informed consent were obtained for creation of a genetic resource. http://
www.cls.ioe.ac.uk/
Exome sequencing
We prepared DNA libraries from 1.5 μg blood-derived genomic DNA using the Paired-End
DNA Sample Preparation Kit (Ilumina). DNA was fragmented using Covaris technology
and the libraries were prepared without gel size selection. We performed target enrichment
using the TruSeq Exome Enrichment Kit (Illumina) targeting 62 Mb of the human genome.
The captured DNA libraries were PCR amplified using the supplied paired-end PCR
primers. Sequencing was performed with an Illumina HiSeq2000 generating 2 × 101 bp
reads.
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Exome variant calling and de novo mutation detection
We mapped sequencing reads to the human reference genome (hg19) using Stampy version
1.0.1426. Duplicate reads were flagged using Picard version 1.60 (http://
picard.sourceforge.net). Median coverage of the target at 15× was 91% across the 1030
individuals (1000 controls and 30 individuals from the 10 overgrowth trios), with a median
of 47,215,315 reads mapping to the target. We used Platypus version 0.1.5 to perform
variant calling27 and SAVANT, a custom strand-aware variant annotation tool written in
Python which follows HGVS nomenclature and ensures consistent annotation of indels,
shifting them to their most 3′ position in the transcript. This script is available on request.
We used an R script to identify variants present in cases but not either parent which is
available on request.
DNMT3A mutation analysis
We performed Sanger sequencing of PCR products from genomic DNA to confirm the
mutations identified by exome sequencing, and to mutationally analyse the gene in the
overgrowth series. We designed PCR primers to amplify the 22 coding exons and intron-
exon boundaries of DNMT3A in 4 multiplex PCR reactions (Supplementary Table 1). The
PCR was carried out using a Qiagen Multiplex PCR kit according to the manufacturer’s
instructions. Products were sequenced with the original PCR primers or internal sequencing
primers (exons 3, 6, 8, 10, 14 and 22) using the BigDye Terminator Cycle Sequencing Kit
and an ABI 3730 Genetic Analyzer (Applied Biosystems, Foster City, CA,USA). Sequences
were analyzed using Mutation Surveyor software v3.97 (SoftGenetics, State College, PA,
USA), and verified by manual inspection. All mutations were confirmed by bidirectional
sequencing of a second, independently amplified PCR product.
Statistical Analysis
The frequency of mutations in cases and controls was compared using a two-sided Fisher’s
exact test.
Protein structure modelling of mutations
The model of the DNMT3A-DNMT3L complex was created using the crystal structures of
the DNMT3A ADD domain (PDB 3A1B), the DNMT3A MTase domain (PDB 2QRV) and
full length DNMT3L (PDB 2PVC). The bound DNA was positioned by superposing the
crystal structure of bacterial cytosine methyltransferase HhaI in complex with DNA (PDB
1MHT). First, the structure of partial DNMT3L in complex with DNMT3A was superposed
onto the structure of full-length DNMT3L to reveal the interactions of the full length
DNMT3L with DNMT3A. Subsequently, the ADD domain of DNMT3A was positioned by
superposing it onto the homologous region of the second molecule of full-length DNMT3L.
Finally, the DNA was positioned by superposing the crystal structure of bacterial cytosine
methyltransferase HhaI in complex with DNA onto the MTase domain of DNMT3A,
placing the DNA at the SAM/DNA binding region. The image was depicted using PyMOL
visualization software (The PyMOL Molecular Graphics System, Version 1.6.0.0
Schrödinger, LLC.).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
DNMT3A structure and mutations. Schematic representation of the protein structure of
DNMT3A with (a) de novo mutations identified in overgrowth cases placed above the
protein and (b) nonsynonymous variants identified in controls placed below the protein.
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Figure 2.
Characteristic facial appearance DNMT3A overgrowth syndrome.
The mutation, growth parameters and other clinical features are given in Table 1 under the
appropriate COG ID: (a) COG1288; (b) COG1670; (c) COG0422; (d) COG1695; (e)
COG1688; (f) COG0109; (g) COG0553; (h) COG1512. Specific consent to publish facial
photographs was obtained for all individuals.
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Figure 3.
Mutations mapped onto a structural model of the DNMT3A-DNMT3L complex. Two
orientations of a model of the DNMT3A monomer generated by superposition of structures
of the DNMT3A ADD domain (cyan), the DNMT3A MTase domain (light orange) and full-
length DNMTL (green) show mutations in the MTase domain in purple and mutations in the
ADD domain in pink. The histone peptide bound to the ADD domain is shown in orange
and the position of the DNA is inferred by superposition of the structurally homologous
bacterial cytosine methyltransferase HhaI-DNA complex. The model shows that the
mutations in the MTase domain appear to be located at the interaction interface with its
ADD domain and at the interface with DNMT3L. Mutations in the ADD domain are close to
the histone-binding region.
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